Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Examine Danaher's (DHR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Danaher (DHR) Reliance on International Sales: What Investors Need to Know

American Express

New Linde PLC

Microsoft

Texas Instruments

UnitedHealth Group

These seven companies are transforming steady profits into rising passive income streams for investors.

Want to Grow a Passive Income Snowball? Buy These 7 Elite Dividend Growth Stocks.

Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positive, but management seems reluctant to put numbers around their optimism. There might be a reason behind the conservativeness, which I explain in this article.

Understanding Danaher's Cautiousness

On Tuesday, Danaher Corp DHR reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion.

Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating

DHR's third-quarter earnings and sales surpass estimates, benefiting from the solid performance of its Life Sciences and Diagnostics segments.

Danaher Q3 Earnings Surpass Estimates, Diagnostics Sales Up Y/Y

Danaher Corporation (NYSE:DHR ) Q3 2024 Earnings Call Transcript October 22, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer Blair - President and CEO Matt McGrew - EVP and CFO Conference Call Participants Tycho Peterson - Jefferies Michael Ryskin - Bank of America Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Scott Davis - Melius Research Puneet Souda - Leerink Partners Dan Leonard - UBS Jack Meehan - Nephron Research Operator My name is Ashley and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation's Third Quarter 2024 Earnings Results Conference Call.

Danaher Corporation (DHR) Q3 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Danaher (DHR) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Danaher (DHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Danaher (DHR) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $2.02 per share a year ago.

Danaher (DHR) Tops Q3 Earnings and Revenue Estimates

Danaher on Tuesday beat Wall Street estimates for third-quarter profit on strong demand for its diagnostics and bioprocessing businesses, alongside growth in its molecular testing unit.

Danaher beats quarterly profit estimates on strong demand for bioprocessing unit

WASHINGTON , Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024.  All results in this release reflect only continuing operations unless otherwise noted.

Danaher Reports Third Quarter 2024 Results

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Danaher (DHR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.

Exploring Analyst Estimates for Danaher (DHR) Q3 Earnings, Beyond Revenue and EPS

DHR stands to benefit from strength in the clinical diagnostics business, Abcam buyout and shareholder-friendly policies. Softness in the Instrument unit remains a concern.

Danaher to Benefit From Business Strength Amid Headwinds

Canadian National Railway Company

General Electric

Learning from successful hedge funds like Millennium means focusing on minimizing risks. To achieve this, I focus on companies with strong pricing power. They have wide moats and recurring revenue that help protect against economic downturns. I've identified three dividend stocks that stand out for their pricing power, market leadership, and ability to generate sustainable long-term returns.

3 Dividend Titans With Pricing Power Straight From The Hedge Fund Playbook

I reiterate my 'Strong Buy' rating for Danaher, with a one-year price target of $310 per share, citing recovery in bioprocessing and market share gains in molecular testing. Danaher's bioprocessing market shows high-single-digit growth in orders, with stabilization in China, and is expected to sustain recovery in Q3 and FY25. Cepheid's market share gains in molecular testing, including FDA authorization for its Hepatitis C RNA test, highlight Danaher's innovation and growth potential.

Danaher Q3 Preview: Market Share Gains In Molecular Testing

Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Automated and Closed Cell Therapy Market 2024-2029" report has been added to ResearchAndMarkets.com's offering.

Automated and Closed Cell Therapy Market Research 2024-2029 Featuring Leading Players - Danaher, Thermo Fischer Scientific, Lonza, and Sartorius

CME Group

Texas Pacific Land Trust

Union Pacific

I explore the idea of managing a highly concentrated portfolio and share how I narrowed down my highest-conviction dividend investments to just five stocks. I emphasize the importance of choosing reliable companies, future-proof wealth compounders, even in a compact portfolio with limited stock picks. After careful analysis, I present my top five dividend stocks, each chosen for their unique qualities, strong growth potential, and ability to thrive long-term.

The Ultimate 5: My Highest-Conviction Dividend Stocks

WASHINGTON , Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m.

Danaher Schedules Third Quarter 2024 Earnings Conference Call

BREA, Calif. and TEL AVIV, Israel , Sept.

Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

WASHINGTON , Sept. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to holders of record on September 27, 2024.

Danaher Announces Quarterly Dividend

DHR benefits from solid momentum across its Diagnostics segment. However, increasing expenses remain a concern.

Here's Why It is Appropriate to Retain Danaher Stock For Now

WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event.

Danaher Confirms Third Quarter and Full Year 2024 Guidance

Hitachi Ltd

Investors with an interest in Diversified Operations stocks have likely encountered both Hitachi Ltd. (HTHIY) and Danaher (DHR).

HTHIY or DHR: Which Is the Better Value Stock Right Now?

WASHINGTON , Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m.

Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.

Danaher's high valuation and flat 2024 EPS growth might raise eyebrows, but its track record, strategic acquisitions, and long-term growth potential make it a solid buy for those who can. Despite trading at a premium, Danaher's strong history, efficient operations, and potential for double-digit EPS growth in 2025 make it one of the few stocks I'm buying at a lofty price. Danaher's blend of strategic acquisitions and operational efficiency makes it a long-term winner. I'm adding to my position despite the high P/E, expecting strong returns as growth picks up.

Danaher: Lofty Price, Bright Future

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

News for Danaher Stock (DHR)